Related references
Note: Only part of the references are listed.Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer
Jamie E. Chaft et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic Analysis for the Global Burden of Disease Study 2019
Jonathan M. Kocarnik et al.
JAMA ONCOLOGY (2022)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Advances in systemic therapy for non-small cell lung cancer
Meagan Miller et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer
Jamie E. Chaft et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates
Catherine B. Meador et al.
CANCER DISCOVERY (2021)
Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020
Haibo Qiu et al.
CANCER COMMUNICATIONS (2021)
Antitumour immunity regulated by aberrant ERBB family signalling
Shogo Kumagai et al.
NATURE REVIEWS CANCER (2021)
Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
Peter T. Harrison et al.
SEMINARS IN CANCER BIOLOGY (2020)
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Narjust Duma et al.
MAYO CLINIC PROCEEDINGS (2019)
Cancer Progress and Priorities: Lung Cancer
Matthew B. Schabath et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2019)
Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning
Shuo Wang et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
The EGFR-rearranged adenocarcinoma is associated with a high rate of venous thromboembolism
Jing Wang et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer
Jacqulyne P. Robichaux et al.
NATURE MEDICINE (2018)
Higher Lung Cancer Incidence in Young Women Than Young Men in the United States
Ahmedin Jemal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Association between oncogenic status and risk of venous thromboembolism in patients with non-small cell lung cancer
Feifei Dou et al.
RESPIRATORY RESEARCH (2018)
Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma
Elsa Davidsson et al.
MULTIDISCIPLINARY RESPIRATORY MEDICINE (2017)
Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study
Tomoya Kawaguchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers
Aaron M. Chapman et al.
LUNG CANCER (2016)
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Yue-Lun Zhang et al.
Oncotarget (2016)
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma
Prasanta Raghab Mohapatra et al.
EUROPEAN RESPIRATORY JOURNAL (2012)